Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: scott_jiminez who wrote ()	6/4/2000 2:15:00 PM
From: scott_jiminez	Read Replies (1) of 278

An arbitrary starting point. An article in the most recent Nature Neuroscience[June 2000, 3(6)], Cell Replacement Therapies for Central Nervous System Disorders Anders Bj”rklund & Olle Lindvall, pp 537 - 544. (http://www.nature.com/cgi-taf/DynaPage.taf?file=/neuro/journal/v3/n6/full/nn0600_537.html&filetype=pdf but may require fee-based registration) This is a updated assessment of CNS transplant therapy for Parkinson's Disease, Huntington's Disease, seizure suppression in epilepsy, post-cerebral ischemia treatment, and more. The authors have been on top of this field for more than a decade: they provide an academic, relatively objective analysis of this approach to treating these brain disorders. How do we go about comparing progress made in neural transplantation versus developments in gene therapy, pharmacology, etc.?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext